149 related articles for article (PubMed ID: 19584732)
41. Overexpression of intrinsic hypoxia markers HIF1alpha and CA-IX predict for local recurrence in stage T1-T2 glottic laryngeal carcinoma treated with radiotherapy.
Schrijvers ML; van der Laan BF; de Bock GH; Pattje WJ; Mastik MF; Menkema L; Langendijk JA; Kluin PM; Schuuring E; van der Wal JE
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):161-9. PubMed ID: 18722267
[TBL] [Abstract][Full Text] [Related]
42. Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade.
Genega EM; Ghebremichael M; Najarian R; Fu Y; Wang Y; Argani P; Grisanzio C; Signoretti S
Am J Clin Pathol; 2010 Dec; 134(6):873-9. PubMed ID: 21088149
[TBL] [Abstract][Full Text] [Related]
43. Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies.
Al-Ahmadie HA; Alden D; Qin LX; Olgac S; Fine SW; Gopalan A; Russo P; Motzer RJ; Reuter VE; Tickoo SK
Am J Surg Pathol; 2008 Mar; 32(3):377-82. PubMed ID: 18300814
[TBL] [Abstract][Full Text] [Related]
44. Molecular markers of prognosis in renal cell carcinoma: Insight into tumor biology helps define risk and provides targets for therapy.
Wood CG
J Surg Oncol; 2006 Sep; 94(4):264-5. PubMed ID: 16941531
[No Abstract] [Full Text] [Related]
45. Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo.
Said HM; Hagemann C; Staab A; Stojic J; Kühnel S; Vince GH; Flentje M; Roosen K; Vordermark D
Radiother Oncol; 2007 Jun; 83(3):398-405. PubMed ID: 17524506
[TBL] [Abstract][Full Text] [Related]
46. Carbonic anhydrase expression in kidney and renal cancer: implications for diagnosis and treatment.
Oosterwijk E
Subcell Biochem; 2014; 75():181-98. PubMed ID: 24146380
[TBL] [Abstract][Full Text] [Related]
47. HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome.
Trastour C; Benizri E; Ettore F; Ramaioli A; Chamorey E; Pouysségur J; Berra E
Int J Cancer; 2007 Apr; 120(7):1451-8. PubMed ID: 17245699
[TBL] [Abstract][Full Text] [Related]
48. Biomarker discovery in urogenital cancer.
Said J
Biomarkers; 2005 Nov; 10 Suppl 1():S83-6. PubMed ID: 16298916
[TBL] [Abstract][Full Text] [Related]
49. The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis.
Colpaert CG; Vermeulen PB; Fox SB; Harris AL; Dirix LY; Van Marck EA
Breast Cancer Res Treat; 2003 Sep; 81(2):137-47. PubMed ID: 14572156
[TBL] [Abstract][Full Text] [Related]
50. Molecular mechanisms of carbonic anhydrase IX-mediated pH regulation under hypoxia.
Pastorekova S; Ratcliffe PJ; Pastorek J
BJU Int; 2008 Jun; 101 Suppl 4():8-15. PubMed ID: 18430116
[No Abstract] [Full Text] [Related]
51. Sporadic renal hemangioblastoma with CA9, PAX2 and PAX8 expression: diagnostic pitfall in the differential diagnosis from clear cell renal cell carcinoma.
Kuroda N; Agatsuma Y; Tamura M; Martinek P; Hes O; Michal M
Int J Clin Exp Pathol; 2015; 8(2):2131-8. PubMed ID: 25973115
[TBL] [Abstract][Full Text] [Related]
52. The expression of G250/mn/CA9 antigen by flow cytometry: its possible implication for detection of micrometastatic renal cancer cells.
Li G; Passebosc-Faure K; Lambert C; Gentil-Perret A; Blanc F; Oosterwijk E; Mosnier JF; Genin C; Tostain J
Clin Cancer Res; 2001 Jan; 7(1):89-92. PubMed ID: 11205923
[TBL] [Abstract][Full Text] [Related]
53. hERG1 and CA IX expression are associated with disease recurrence in surgically resected clear cell renal carcinoma.
Lastraioli E; Pillozzi S; Mari A; Tellini R; Duranti C; Baldazzi V; Venturini S; Minervini A; Lapini A; Nesi G; Carini M; Arcangeli A
Eur J Surg Oncol; 2020 Jan; 46(1):209-215. PubMed ID: 31679954
[TBL] [Abstract][Full Text] [Related]
54. Carbonic anhydrase IX expression correlates with FDG uptake by primary non-small cell lung cancer.
Mees G; Vangestel C; Dierckx R; Pauwels P; Van Meerbeeck J; Van de Wiele C
Cancer Biother Radiopharm; 2010 Apr; 25(2):149-54. PubMed ID: 20423227
[TBL] [Abstract][Full Text] [Related]
55. The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy.
De Schutter H; Landuyt W; Verbeken E; Goethals L; Hermans R; Nuyts S
BMC Cancer; 2005 Apr; 5():42. PubMed ID: 15847702
[TBL] [Abstract][Full Text] [Related]
56. Target-specific therapy requires target-specific populations in the treatment of renal cell carcinoma.
Figlin RA; Alvin H; Meinhardt CL
Urologe A; 2004 Sep; 43 Suppl 3():S144-5. PubMed ID: 15179554
[No Abstract] [Full Text] [Related]
57. Diagnostic and prognostic molecular markers in renal cell carcinoma.
Tunuguntla HS; Jorda M
J Urol; 2008 Jun; 179(6):2096-102. PubMed ID: 18423738
[TBL] [Abstract][Full Text] [Related]
58. Carbonic anhydrase IX: historical and future perspectives.
Oosterwijk E
BJU Int; 2008 Jun; 101 Suppl 4():2-7. PubMed ID: 18430115
[No Abstract] [Full Text] [Related]
59. Alternative splicing variants of carbonic anhydrase IX in human non-small cell lung cancer.
Malentacchi F; Simi L; Nannelli C; Andreani M; Janni A; Pastorekova S; Orlando C
Lung Cancer; 2009 Jun; 64(3):271-6. PubMed ID: 19022520
[TBL] [Abstract][Full Text] [Related]
60. Carbonic anhydrase IX/G250/MN: a molecule too good to be true?
Oosterwijk E
BJU Int; 2008 Mar; 101(5):527-8. PubMed ID: 18257853
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
